Published in J Diabetes Sci Technol on May 01, 2008
Asynchronous and synchronous teleconsultation for diabetes care: a systematic literature review. J Diabetes Sci Technol (2010) 1.67
Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials. Diabetes Care (2012) 1.12
Precision medicine for managing diabetes. J Diabetes Sci Technol (2015) 1.06
The increasing incidence of diabetes in the 21st century. J Diabetes Sci Technol (2009) 0.80
Migraine in the era of precision medicine. Ann Transl Med (2016) 0.76
The personalized medicine for diabetes meeting summary report. J Diabetes Sci Technol (2009) 0.76
A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes. Diabetes Ther (2014) 0.76
Diabetes telehealth and computerized decision support systems: a sound system with a human touch is needed. J Diabetes Sci Technol (2010) 0.75
Intelligent Techniques Using Molecular Data Analysis in Leukaemia: An Opportunity for Personalized Medicine Support System. Biomed Res Int (2017) 0.75
Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA (2006) 11.78
Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw (2006) 7.19
Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet (2007) 6.55
Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J (2001) 5.94
Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care (2005) 5.56
Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care (2006) 4.53
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
Etiology of insulin resistance. Am J Med (2006) 4.44
Genetic factors in type 2 diabetes: the end of the beginning? Science (2005) 2.37
DNA sequencing: bench to bedside and beyond. Nucleic Acids Res (2007) 2.25
Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes (2008) 2.15
Smart Vest: wearable multi-parameter remote physiological monitoring system. Med Eng Phys (2007) 2.03
Screening for insulitis in adult autoantibody-positive organ donors. Diabetes (2007) 2.02
Inflammatory process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci (2006) 1.99
Common sense for our genomes. Nature (2007) 1.90
Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol (2007) 1.86
The prospects for "personalized medicine" in drug development and drug therapy. Clin Pharmacol Ther (2007) 1.78
1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn (2008) 1.78
The artificial pancreas: how sweet engineering will solve bitter problems. J Diabetes Sci Technol (2007) 1.73
Genome-wide association to body mass index and waist circumference: the Framingham Heart Study 100K project. BMC Med Genet (2007) 1.64
Neonatal diabetes mellitus: a disease linked to multiple mechanisms. Orphanet J Rare Dis (2007) 1.61
Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care (2007) 1.59
Identification of a molecular signature in human type 1 diabetes mellitus using serum and functional genomics. J Immunol (2008) 1.43
Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol Psychiatry (2007) 1.41
Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr J (2006) 1.41
Serum retinol-binding protein: a link between obesity, insulin resistance, and type 2 diabetes. Nutr Rev (2007) 1.37
The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab (2006) 1.36
Common variants in maturity-onset diabetes of the young genes and future risk of type 2 diabetes. Diabetes (2008) 1.35
Skipping toward personalized molecular medicine. N Engl J Med (2007) 1.30
Exhaled methyl nitrate as a noninvasive marker of hyperglycemia in type 1 diabetes. Proc Natl Acad Sci U S A (2007) 1.28
Minireview: pharmacogenetics and beyond: the interaction of therapeutic response, beta-cell physiology, and genetics in diabetes. Endocrinology (2006) 1.22
Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract (2006) 1.17
Optimizing the therapeutic benefits of exercise in Type 2 diabetes. J Appl Physiol (1985) (2007) 1.16
The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vascul Pharmacol (2006) 1.13
Dietary advice for treatment of type 2 diabetes mellitus in adults. Cochrane Database Syst Rev (2007) 1.11
Moving towards efficient therapies in type 1 diabetes: to combine or not to combine? Autoimmun Rev (2006) 1.09
Adiponectin independently predicts metabolic syndrome in overweight Latino youth. J Clin Endocrinol Metab (2007) 1.06
Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des (2007) 0.98
Systems biology: the case for a systems science approach to diabetes. J Diabetes Sci Technol (2008) 0.98
Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus. Scand J Clin Lab Invest (2007) 0.97
Pathological mechanisms involved in diabetic neuropathy: can we slow the process? Curr Opin Investig Drugs (2006) 0.96
Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst Rev (2007) 0.95
Proinflammatory circulating molecules in peripheral arterial disease. Int J Mol Med (2007) 0.95
Wrist ambulatory monitoring system and smart glove for real time emotional, sensorial and physiological analysis. Conf Proc IEEE Eng Med Biol Soc (2004) 0.94
Type 1 diabetes risk analysis on dried blood spot samples from population-based newborns: design and feasibility of an unselected case-control study. Paediatr Perinat Epidemiol (2007) 0.92
Prime suspect: the TCF7L2 gene and type 2 diabetes risk. J Clin Invest (2007) 0.92
Prevention of Type 2 diabetes: fact or fiction? Expert Opin Pharmacother (2007) 0.91
Gene discovery in diabetic nephropathy. Curr Diab Rep (2007) 0.90
Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest (2007) 0.90
Physical activity modifies the effect of SNPs in the SLC2A2 (GLUT2) and ABCC8 (SUR1) genes on the risk of developing type 2 diabetes. Physiol Genomics (2007) 0.90
Foundations, promises and uncertainties of personalized medicine. Mt Sinai J Med (2007) 0.87
Diagnosis and management of maturity-onset diabetes of the young. Treat Endocrinol (2005) 0.87
Immune intervention at diagnosis--should we treat children to preserve beta-cell function? Pediatr Diabetes (2007) 0.86
Dyslipidemia in type 2 diabetes mellitus. Curr Diab Rep (2007) 0.85
Differential diagnosis of type 1 diabetes: which genetic syndromes need to be considered? Pediatr Diabetes (2007) 0.84
Nutrigenetics. Forum Nutr (2007) 0.84
Can thiazolidinediones delay disease progression in type 2 diabetes? Curr Med Res Opin (2006) 0.82
The status of gene vectors for the treatment of diabetes. Cell Biochem Biophys (2007) 0.82
Finding GAD: early detection of beta-cell injury. Endocrinology (2007) 0.82
Preventing microalbuminuria in patients with type 2 diabetes. Diabetes Metab Res Rev (2007) 0.82
The prospect of vaccination to prevent type 1 diabetes. Hum Vaccin (2005) 0.81
Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation? Endocrinol Metab Clin North Am (2005) 0.81
Insulin pump therapy (continuous subcutaneous insulin infusion). Prim Care (2007) 0.81
Amino-terminal brain natriuretic peptide is related to the presence of diabetic polyneuropathy independently of cardiovascular disease. Diabetes Care (2007) 0.80
Autoantibodies in diabetes mellitus: current utility and perspectives. Exp Clin Endocrinol Diabetes (2007) 0.79
Protein microarray analysis as a tool for monitoring cellular autoreactivity in type 1 diabetes patients and their relatives. Pediatr Diabetes (2007) 0.79
The next generation of artificial pancreas control algorithms. J Diabetes Sci Technol (2008) 0.79
Pharmacogenetics of glucose-lowering drug treatment: a systematic review. Mol Diagn Ther (2007) 0.78
Complexity of type 2 diabetes mellitus data sets emerging from nutrigenomic research: a case for dimensionality reduction? Mutat Res (2007) 0.77
Latent autoimmune diabetes in adults: increased awareness will aid diagnosis. Ann Clin Biochem (2007) 0.77
Despite glacial progress, US government signals support for personalized medicine. Nat Biotechnol (2007) 0.77
The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes. Expert Opin Pharmacother (2007) 0.77
Detection of hypoglycemic episodes in children with type 1 diabetes using an optimal Bayesian neural network algorithm. Conf Proc IEEE Eng Med Biol Soc (2007) 0.77
Impact of the US Patent System on the promise of personalized medicine. Gend Med (2007) 0.76
Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care (2007) 0.76
Generating new candidate genes for neonatal diabetes: functional and genetic studies of insulin secretion in type 2 diabetes. Endocr Dev (2007) 0.76
Autoimmune diabetes mellitus with adult onset and type 1 diabetes mellitus in children have different genetic predispositions. Ann N Y Acad Sci (2007) 0.76
Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med (2013) 6.64
Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther (2013) 2.85
Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther (2012) 2.46
The missing element of telemedicine for diabetes: decision support software. J Diabetes Sci Technol (2009) 1.83
Time synching or time sinking? Diabetes Technol Ther (2005) 1.70
The need for separate performance goals for glucose sensors in the hypoglycemic, normoglycemic, and hyperglycemic ranges. Diabetes Care (2004) 1.55
Using telemedicine to improve outcomes in diabetes--an emerging technology. J Diabetes Sci Technol (2009) 1.52
Blood glucose meter market: this world is undergoing drastic changes. J Diabetes Sci Technol (2013) 1.51
Assisted monitoring of blood glucose: special safety needs for a new paradigm in testing glucose. J Diabetes Sci Technol (2010) 1.48
Technical aspects of the Parkes error grid. J Diabetes Sci Technol (2013) 1.41
Second insulin pump safety meeting: summary report. J Diabetes Sci Technol (2010) 1.40
A review of the security of insulin pump infusion systems. J Diabetes Sci Technol (2011) 1.34
Regulatory controversies surround blood glucose monitoring devices. J Diabetes Sci Technol (2010) 1.32
New evidence demonstrates that self-monitoring of blood glucose does not improve outcomes in type 2 diabetes-when this practice is not applied properly. J Diabetes Sci Technol (2008) 1.15
The need for clinical accuracy guidelines for blood glucose monitors. J Diabetes Sci Technol (2012) 1.14
Diabetes and telemedicine: is the technology sound, effective, cost-effective, and practical? Diabetes Care (2003) 1.11
SMBG out of control: the need for educating patients about control solution. Diabetes Educ (2013) 0.99
Designing an artificial pancreas system to be compatible with other medical devices. J Diabetes Sci Technol (2008) 0.99
The current status of bolus calculator decision-support software. J Diabetes Sci Technol (2012) 0.97
Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol (2013) 0.97
Technology to treat hyperglycemia in trauma. J Diabetes Sci Technol (2007) 0.94
Subcutaneous continuous glucose monitoring in severe burn patients. Crit Care Med (2007) 0.92
Quality Control of Insulins and Biosimilar Insulins: What Do We Know? J Diabetes Sci Technol (2016) 0.91
Hypoglycemia begets hypoglycemia: the order effect in the ASPIRE in-clinic study. Diabetes Technol Ther (2014) 0.90
Point-of-Care Blood Glucose Meter Accuracy in the Hospital Setting. Diabetes Spectr (2014) 0.90
Improved outcomes from diabetes monitoring: the benefits of better adherence, therapy adjustments, patient education, and telemedicine support. J Diabetes Sci Technol (2012) 0.89
Twelve modern digital technologies that are transforming decision making for diabetes and all areas of health care. J Diabetes Sci Technol (2013) 0.88
Improving the safety of blood glucose monitoring. J Diabetes Sci Technol (2011) 0.86
The ASPIRE study: design and methods of an in-clinic crossover trial on the efficacy of automatic insulin pump suspension in exercise-induced hypoglycemia. J Diabetes Sci Technol (2011) 0.86
Spending for diabetes drugs is increasing in the United States. J Diabetes Sci Technol (2008) 0.81
The increasing incidence of diabetes in the 21st century. J Diabetes Sci Technol (2009) 0.80
United Kingdom prospective diabetes study follow-up studies establish a legacy effect of therapy for hyperglycemia but not hypertension. J Diabetes Sci Technol (2008) 0.79
The need for performance standards for continuous glucose monitors. J Diabetes Sci Technol (2007) 0.78
Hospital diabetes: why quality of care matters to both patients and hospitals. J Diabetes Sci Technol (2011) 0.78
A sweetened beverage tax is needed to combat the obesity epidemicas well as related absenteeism and presenteeism. J Diabetes Sci Technol (2009) 0.78
The benefits of implanted glucose sensors. J Diabetes Sci Technol (2007) 0.78
The need for a glycemia modeling comparison workshop to facilitate development of an artificial pancreas. J Diabetes Sci Technol (2010) 0.78
The beneficial effects of a Paleolithic diet on type 2 diabetes and other risk factors for cardiovascular disease. J Diabetes Sci Technol (2009) 0.77
Microdialysis of interstitial fluid for continuous glucose measurement. Diabetes Technol Ther (2003) 0.76
Business and economics of diabetes. J Diabetes Sci Technol (2008) 0.76
Glutamic Acid decarboxylase therapy for recent-onset type 1 diabetes: are we at the end or the beginning of finding a cure? J Diabetes Sci Technol (2009) 0.75
Fibroblast growth factor: will this hormone be the hemoglobin A1c for managing phosphorus balance in chronic kidney disease? J Diabetes Sci Technol (2010) 0.75
Bariatric surgery for obese adolescents. J Diabetes Sci Technol (2007) 0.75
The link between diabetes, military metabolic monitoring, and NASA. Diabetes Technol Ther (2003) 0.75
Dirlotapide, a U.S. Food and Drug Administration-approved first-in-class obesity drug for dogs-will humans be next? J Diabetes Sci Technol (2007) 0.75
The "catalyst to better diabetes care act of 2007". J Diabetes Sci Technol (2008) 0.75
Freedom of speech and science: can companies force us to withdraw data they don't like? J Diabetes Sci Technol (2013) 0.75
Pyruvate therapy for severe hypoglycemia. Diabetes Technol Ther (2005) 0.75
European trends in diabetes technology--continuous glucose measurements and computerized information-processing tools. Diabetes Technol Ther (2002) 0.75
The First Annual Diabetes Technology Meeting--a new forum for accelerating the development of technology to fight diabetes. Diabetes Technol Ther (2002) 0.75
Current, emerging, and future trends in metabolic monitoring. Diabetes Technol Ther (2002) 0.75
An adaptive drug infusion system. Diabetes Technol Ther (2004) 0.75
The new food and drug administration center for devices and radiological health engineering and physics laboratory and methods for testing software that controls infusion pumps. J Diabetes Sci Technol (2007) 0.75
Technology for portable measurement of blood lactate. Diabetes Technol Ther (2003) 0.75